Traditionally hormone-driven, prostate cancer therapy has advanced beyond androgen deprivation.
- Androgen Receptor Pathway Inhibitors: abiraterone (Zytiga®), enzalutamide (Xtandi®), apalutamide (Erleada®), and darolutamide (Nubeqa®) prolong survival in both metastatic hormone-sensitive and castration-resistant disease.
- Radioligand Therapy: Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) delivers targeted radiation to PSMA-positive cancer cells.
- PARP Inhibitors: Olaparib and rucaparib show benefit in BRCA1/2-mutated or HRR- deficient tumors.